TheraRadar
← Back
Data updated: May 24, 2026

Baxter

Specialty
Infectious DiseaseCardiovascularOncology Execution: Excellent

Baxter is a specialty pharmaceutical company focused on Infectious Disease, Cardiovascular, Oncology. Key products include EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE.

1951
Since
311
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
32 Small Molecules 4 Biologics

Baxter at a Glance

  • Strong track record with 82% execution quality across 25 trials
  • Fast trial execution (8 months median completion)

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

EPINEPHRINE NDA
2026-03-30
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
BENDAMUSTINE HYDROCHLORIDE NDA
2025-07-03
bendamustine hydrochloride
EPINEPHRINE NDA
2025-03-13
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE NDA
2025-02-28
epinephrine bitartrate
Simple dental procedures
BORTEZOMIB NDA
2024-08-26
bortezomib
VASOPRESSIN IN SODIUM CHLORIDE 0.9% NDA
2024-07-11
vasopressin
Vasodilatory Shock

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Infectious Disease 24%
12 drugs
Cardiovascular 22%
11 drugs
Oncology 19%
9 drugs Phase 1: 1
Dermatology 18%
9 drugs
Metabolic 16%
8 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 6/7 completed
  • • Speed: 8 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges